Hôpital Henri-Mondor AP-HP

62 currently recruiting clinical trials
Create patient profile for matching
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Henri-Mondor AP-HP (Créteil)
Daiichi Sankyo
Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00
Cohorte C
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Bispecific T-cell engager antibodies
Hôpital Henri-Mondor AP-HP (Créteil)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00
Cohorte B
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies
Hôpital Henri-Mondor AP-HP (Créteil)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
Hôpital Henri-Mondor AP-HP (Créteil)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Acute leukemia #NCT07007052 #2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Hôpital Henri-Mondor AP-HP (Créteil)
French Innovative Leukemia Organisation (FILO)
Phase 2 Lymphoma #NCT06271057 #2023-506705-20-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
Hôpital Henri-Mondor AP-HP (Créteil)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Sarcoma and GIST Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic types
Stomach Oesogastric junction Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma Ampullary carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1) CPS Positive (1 <= X < 5)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
Hôpital Henri-Mondor AP-HP (Créteil)
UNICANCER
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
Hôpital Henri-Mondor AP-HP (Créteil)
UNICANCER
Phase 2 Acute leukemia #NCT07007052 #2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Hôpital Henri-Mondor AP-HP (Créteil)
French Innovative Leukemia Organisation (FILO)
Phase 2 Lymphoma #NCT04844866
Partie II
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Follicular lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive Car-T
Hôpital Henri-Mondor AP-HP (Créteil)
Miltenyi Biomedicine GmbH